FORMA Announces Oral and Poster Presentations at Upcoming 2019 ASH Annual Meeting
Retrieved on:
Wednesday, November 6, 2019
FORMA Therapeutics , Inc., a clinical stage biopharmaceutical company focused on rare hematological diseases and cancers, today announced that three abstracts have been accepted for presentation at the 61st American Society of Hematology (ASH) Annual Meeting being held in Orlando, Florida from December 7-10, 2019.
Key Points:
- FORMA Therapeutics , Inc., a clinical stage biopharmaceutical company focused on rare hematological diseases and cancers, today announced that three abstracts have been accepted for presentation at the 61st American Society of Hematology (ASH) Annual Meeting being held in Orlando, Florida from December 7-10, 2019.
- A poster presentation will feature data for a FORMA-discovered asset licensed to Celgene Corporation, FT-1101, an oral, structurally distinct and potent pan-inhibitor of the Bromodomain and Extra-Terminal (BET) epigenetic protein family.
- The downstream activity of FT-4202 increases ATP levels, the fuel that provides energy to cells, to improve RBC health and survival.
- FORMA Therapeutics is focused on the discovery, development and commercialization of transformative medicines that will make a difference for patients with hematologic, oncologic, and metabolic diseases.